Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
University of Miami
mi
from
Miami, FL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Rush University Medical Center
mi
from
Chicago, IL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
University of Chicago Medicine
mi
from
Chicago, IL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
NorthShore University Health System
mi
from
Evanston, IL
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Gastroenterology Associates
mi
from
Baton Rouge, LA
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Gastroenterology Associates
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
MGG Group, Co. Inc./Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
MGG Group, Co. Inc./Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Massachusetts General Hospital
mi
from
Boston, MA
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Boston Med Ctr
mi
from
Boston, MA
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Detroit Clinical Research Center PC
mi
from
Farmington Hills, MI
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Detroit Clinical Research Center PC
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
The Mayo Clinic
mi
from
Rochester, MN
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Center for Digestive & Liver Diseases Inc.
mi
from
Mexico, MO
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Center for Digestive & Liver Diseases Inc.
mi
from
Mexico, MO
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Medical Research Associates of New York
mi
from
New York, NY
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Medical Research Associates of New York
mi
from
New York, NY
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Asheville Gastroeneterology Associates
mi
from
Asheville, NC
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Asheville Gastroeneterology Associates
mi
from
Asheville, NC
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Univeristy of North Carolina
mi
from
Chapel Hill, NC
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Univeristy of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Cleveland Clinic
mi
from
Cleveland, OH
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Houston Methodist Hospital
mi
from
Houston, TX
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Advanced Research Institute
mi
from
Logan, UT
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Advanced Research Institute
mi
from
Logan, UT
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Blue Ridge Medical Research
mi
from
Lynchburg, VA
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Blue Ridge Medical Research
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated:  2/16/2017
University of Calgary
mi
from
Calgary,
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study
Status: Enrolling
Updated: 2/16/2017
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Orange, CA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
St.Petersburg, FL
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
St.Petersburg, FL
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Covington, LA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Covington, LA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Baltimore, MD
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Boston, MA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Boston, MA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Boston, MA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Tualatin, OR
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Tualatin, OR
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Providence, RI
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Nashville, TN
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
University of California, Irvine Medical Center
mi
from
Orange, CA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Florida Cancer Specialists.
mi
from
St.Petersburg, FL
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Florida Cancer Specialists.
mi
from
St.Petersburg, FL
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Dana-Farber Cancer Inst
mi
from
Boston, MA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Oklahoma University Health Sciences Center
mi
from
Oklahoma City, OK
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Oklahoma University Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Magee-Womens Hospital
mi
from
Pittsburgh, PA
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Magee-Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Women and Infants Hospital
mi
from
Providence, RI
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated:  2/16/2017
UZ Leuven Gasthuisberg
mi
from
Leuven,
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Status: Enrolling
Updated: 2/16/2017
UZ Leuven Gasthuisberg
mi
from
Leuven,
Click here to add this to my saved trials
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/18/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/18/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/18/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/18/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials